Krystal Biotech (NASDAQ:KRYS) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a report published on Wednesday morning,Benzinga reports. The firm currently has a $221.00 price objective on the stock.

Other analysts have also issued research reports about the company. Citigroup increased their target price on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. William Blair raised Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Chardan Capital reissued a “buy” rating and issued a $212.00 price target on shares of Krystal Biotech in a research report on Thursday, December 12th. Stifel Nicolaus upped their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $206.67.

Krystal Biotech Stock Performance

Shares of KRYS traded up $1.35 during mid-day trading on Wednesday, reaching $157.99. 36,069 shares of the company’s stock traded hands, compared to its average volume of 321,479. Krystal Biotech has a 12 month low of $107.50 and a 12 month high of $219.34. The stock has a market capitalization of $4.54 billion, a P/E ratio of 89.26 and a beta of 0.80. The business’s 50-day moving average price is $180.70 and its 200-day moving average price is $185.17.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm’s quarterly revenue was up 879.9% on a year-over-year basis. During the same period last year, the company posted ($0.67) EPS. Equities research analysts anticipate that Krystal Biotech will post 2.97 EPS for the current year.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 14.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently made changes to their positions in the company. Key Financial Inc acquired a new position in Krystal Biotech in the second quarter valued at about $28,000. Blue Trust Inc. increased its stake in Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after purchasing an additional 163 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Krystal Biotech during the third quarter worth about $40,000. Values First Advisors Inc. acquired a new position in Krystal Biotech during the 3rd quarter worth approximately $53,000. Finally, Quest Partners LLC bought a new position in Krystal Biotech in the second quarter valued at $71,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).